These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 15546111

  • 1. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
    File TM.
    Clin Infect Dis; 2004 Sep 01; 39 Suppl 3():S159-64. PubMed ID: 15546111
    [Abstract] [Full Text] [Related]

  • 2. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP, Zhanel GG.
    Semin Respir Crit Care Med; 2009 Apr 01; 30(2):210-38. PubMed ID: 19296420
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec 01; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 4. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May 01; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN, Fritsche TR, Sader HS.
    Diagn Microbiol Infect Dis; 2005 Jun 01; 52(2):129-33. PubMed ID: 15964501
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sparfloxacin: a review.
    Schentag JJ.
    Clin Ther; 2000 Apr 01; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [Abstract] [Full Text] [Related]

  • 8. Short-duration therapy for respiratory tract infections.
    Goff DA.
    Ann Pharmacother; 2004 Sep 01; 38(9 Suppl):S19-23. PubMed ID: 15226490
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
    Li JZ, Winston LG, Moore DH, Bent S.
    Am J Med; 2007 Sep 01; 120(9):783-90. PubMed ID: 17765048
    [Abstract] [Full Text] [Related]

  • 10. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM.
    Infection; 2005 Jun 01; 33(3):106-14. PubMed ID: 15940410
    [Abstract] [Full Text] [Related]

  • 11. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV.
    Expert Rev Anti Infect Ther; 2006 Oct 01; 4(5):821-35. PubMed ID: 17140358
    [Abstract] [Full Text] [Related]

  • 12. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J, House HR, Siegel RE.
    Am J Med; 2005 Jul 01; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [Abstract] [Full Text] [Related]

  • 13. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
    File TM, Schentag JJ.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S157-65. PubMed ID: 18986283
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb 01; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 15. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1071. PubMed ID: 12736860
    [No Abstract] [Full Text] [Related]

  • 16. Clarithromycin in the management of community-acquired pneumonia.
    McCarty JM.
    Clin Ther; 2000 Mar 09; 22(3):281-94; discussion 265. PubMed ID: 10963284
    [Abstract] [Full Text] [Related]

  • 17. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J, Martín-Herrero JE, Mykietiuk A, García-Rey C.
    Clin Microbiol Infect; 2006 May 09; 12 Suppl 3():2-11. PubMed ID: 16669924
    [Abstract] [Full Text] [Related]

  • 18. [Antibiotic therapy for community acquired Streptococcus pneumoniae pneumonia: clinical relevance of antibiotic resistance].
    Bédos JP, Bruneel F.
    Med Mal Infect; 2006 May 09; 36(11-12):667-79. PubMed ID: 16842956
    [Abstract] [Full Text] [Related]

  • 19. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
    Lynch JP, Zhanel GG.
    Semin Respir Crit Care Med; 2005 Dec 09; 26(6):575-616. PubMed ID: 16388429
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J.
    Int J Clin Pract; 2005 Nov 09; 59(11):1253-9. PubMed ID: 16236076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.